INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...

Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

You might resent having to pay premiums, but when disaster or just a minor fender-bender happens, you'll be happy you have ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Andy Reid is a three-time Super Bowl champion, potentially looking to add some more hardware to the mantle to conclude this ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

Wall Street drifted through a mixed day of trading as rising fashion and cigarette stocks worked against drops for Ford Motor ...